Azilsartan Tablets
The active-drug concept underpins the market and is widely recognized across regional formulations. Tablet dosing supports once-daily chronic hypertension management.
Size, Share & Industry Analysis, By Type (Azilsartan Tablets, Azilsartan Medoxomil Tablets), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others), By End User (Hospitals, Specialty Clinics, Homecare), By Prescription Pattern (First-Line Therapy, Second-Line Therapy, Combination Therapy), By Therapeutic Approach (Monotherapy, Step-Up Therapy, Maximal Therapy), and Regional Forecast, 2026-2034
The global Azilsartan market was valued at USD 580 million in 2025 and is estimated at USD 605.2 million in 2026. The market is projected to reach USD 850 million by 2034, exhibiting a 4.3% CAGR during 2026–2034.
Azilsartan is an angiotensin II receptor blocker used to treat hypertension by selectively blocking the AT1 receptor and reducing angiotensin-II-mediated vasoconstriction and aldosterone effects. In the United States, the marketed oral product is azilsartan medoxomil, a prodrug rapidly converted to active azilsartan during absorption. Current labeling covers 40 mg and 80 mg tablets and permits use alone or with other antihypertensive agents.
The treatment base is large. WHO estimates that 1.4 billion adults aged 30–79 had hypertension in 2024, yet only about 23% had their blood pressure controlled. This persistent control gap creates demand for effective chronic oral therapy, including angiotensin receptor blockers. The 2025 U.S. high-blood-pressure guideline includes azilsartan among the ARB options at 40–80 mg once daily and emphasizes a general treatment goal below 130/80 mm Hg for most adults.
The market is increasingly influenced by generic competition and fixed-dose combinations. Lupin received the first U.S. generic approvals for azilsartan medoxomil 40 mg and 80 mg tablets in 2022. Alkem received first generic approval in January 2025 for azilsartan medoxomil/chlorthalidone 40/12.5 mg and 40/25 mg tablets, while the current single-agent NDA label was repackaged and marketed by Wilshire Pharmaceuticals beginning in April 2026. These changes improve availability but increase price competition around the original Edarbi franchise.
The study covers azilsartan and azilsartan-medoxomil oral products used in hypertension, preserving the source segmentation by formulation, distribution, end user, prescription pattern and therapeutic approach.
| Report Attribute | Coverage |
|---|---|
| Base Year | 2025 |
| Estimated Year | 2026 |
| Forecast Period | 2026–2034 |
| Market Measurement | Revenue, USD million |
| By Type | Azilsartan Tablets; Azilsartan Medoxomil Tablets |
| By Application / Distribution | Hospital Pharmacy; Retail Pharmacy; Online Pharmacy; Others |
| By End User | Hospitals; Specialty Clinics; Homecare |
| By Prescription Pattern | First-Line Therapy; Second-Line Therapy; Combination Therapy |
| By Therapeutic Approach | Monotherapy; Step-Up Therapy; Maximal Therapy |
| By Strength | 40 mg; 80 mg |
| By Region | North America; Europe; Asia-Pacific; Latin America; Middle East & Africa |
| Key Market Players | Takeda Pharmaceutical Company Limited; Lupin Limited; Jiangsu Hengrui Pharmaceuticals; Cipla Limited; Dr. Reddy's Laboratories; Zydus Lifesciences; Teva Pharmaceutical Industries; Aurobindo Pharma; Viatris; Sun Pharmaceutical Industries; Glenmark Pharmaceuticals; Torrent Pharmaceuticals; Wockhardt; Micro Labs; USV Private Limited; Wilshire Pharmaceuticals / Azurity; Alkem Laboratories |
WHO reports 1.4 billion adults aged 30–79 with hypertension, with only about 320 million having the condition controlled. Chronic treatment need remains substantial across all major regions.
The 2025 AHA/ACC guideline continues to list ARBs as a first-line antihypertensive class and includes azilsartan at 40–80 mg once daily. This supports its clinical relevance even in a crowded generic ARB market.
Lupin's first single-agent U.S. generic approval and Alkem's 2025 first generic azilsartan/chlorthalidone approval illustrate increasing competition around the franchise. Lower prices can expand access but compress market value per prescription.
Losartan, valsartan, candesartan, telmisartan and olmesartan have broad generic availability and long clinical familiarity. Payers often favor lower-cost alternatives unless azilsartan's blood-pressure profile or patient response supports its use.
Current U.S. labeling carries a boxed warning for fetal toxicity and warns about hypotension, impaired renal function and hyperkalemia in susceptible patients, requiring appropriate patient selection and monitoring.
Azilsartan medoxomil combined with chlorthalidone provides an option for patients requiring two antihypertensive agents. Alkem's 2025 U.S. first generic approval for the 40/12.5 mg and 40/25 mg strengths broadens competition in this combination segment.
The 2025 U.S. guideline states that adults with stage 2 hypertension should generally begin treatment with two first-line agents of different classes in a single-pill fixed-dose combination when appropriate, reinforcing the commercial relevance of ARB combination products.
Hypertension treatment is long term and stable patients often receive repeat prescriptions. Digital pharmacy and mail-order distribution can reduce refill friction, particularly for chronic generic products.
WHO's South-East Asia statement in May 2026 cited more than 273 million people with hypertension in that region alone, with almost eight in ten not controlled. Expanding diagnosis and generic access create a large potential treatment pool.
As exclusivity and market ownership evolve, lower acquisition cost can improve formulary placement and broaden use among payers and patients who previously selected older lower-cost ARBs.
Azilsartan competes within the first-line ARB class and is used either alone or as part of combination antihypertensive therapy.
| Clinical / Treatment Context | Role of Azilsartan | Market Relevance |
|---|---|---|
| Uncomplicated hypertension | Once-daily ARB therapy when medication treatment is indicated. | Largest broad treatment setting. |
| Stage 2 hypertension | Can be paired with another first-line agent, including a thiazide-like diuretic. | Supports combination-therapy growth. |
| Patients intolerant of ACE inhibitors | ARBs can be selected when ACE-inhibitor cough or other intolerance makes an ARB preferable. | Maintains class-level demand. |
| Resistant / difficult-to-control hypertension | May be used within multidrug regimens under specialist supervision. | Important specialty-clinic niche. |
| Older adults / CKD-risk patients | Requires monitoring of renal function, potassium and volume status according to patient characteristics. | Raises importance of individualized prescribing. |
Azilsartan Tablets form the broad commercial base, while Azilsartan Medoxomil Tablets are the principal prodrug formulation used in current U.S. products.
The active-drug concept underpins the market and is widely recognized across regional formulations. Tablet dosing supports once-daily chronic hypertension management.
Azilsartan medoxomil is converted to active azilsartan during absorption and is marketed in 40 mg and 80 mg strengths. Current U.S. labeling recommends 80 mg once daily for most adults.
Hospital Pharmacy is the leading source-model channel, while retail and online channels provide most refill convenience for stable chronic patients.
Hospital pharmacies support treatment initiation, specialist prescribing and management of patients with cardiovascular or renal comorbidities.
Retail pharmacies remain important for monthly or 90-day refills of chronic antihypertensive therapy and are central to generic substitution.
Mail-order and online pharmacy services reduce refill friction and can support long-term adherence in stable patients.
Integrated delivery networks, specialty mail-order programs and regional government procurement can contribute depending on country structure.
Hospitals form the largest institutional end-user segment in the source model, while specialty clinics and homecare support long-term chronic management.
Hospital and health-system physicians initiate or adjust therapy in patients with uncontrolled hypertension and comorbid cardiovascular or renal disease.
Cardiology and hypertension clinics manage difficult-to-control patients and multidrug regimens where selection among ARBs may be more individualized.
Once treatment is stabilized, azilsartan is taken daily at home. Home blood-pressure monitoring and refill convenience therefore influence long-term persistence.
Combination Therapy has the strongest growth potential, while first- and second-line use depend on payer policy, patient characteristics and physician preference among ARBs.
ARBs are first-line antihypertensive drugs in current U.S. guidance. Azilsartan competes with numerous lower-cost generic ARBs within this broad first-line category.
Azilsartan can be introduced when blood pressure remains uncontrolled or another agent is not tolerated, creating stable second-line demand.
Single-pill and multi-pill combinations are increasingly used to reach guideline-recommended blood-pressure targets more rapidly, supporting azilsartan/chlorthalidone and other combination approaches.
Step-Up Therapy is the dominant approach because antihypertensive treatment is progressively intensified according to blood-pressure response and overall cardiovascular risk.
A single ARB may be sufficient for selected patients with less severe hypertension or when treatment is being initiated cautiously.
Dose adjustment and addition of complementary antihypertensive classes are common when target blood pressure is not achieved, making step-up treatment the dominant practical pathway.
Patients with resistant hypertension may require three or more drug classes and specialist monitoring. This segment is smaller but clinically complex.
North America is the largest regional market. The United States was approximately USD 210 million in 2025 and has mature hypertension diagnosis, reimbursement and pharmacy distribution. Current FDA and DailyMed records confirm active marketing of 40 mg and 80 mg azilsartan medoxomil tablets.
Europe is a mature antihypertensive market with strong generic substitution and national price controls. Germany, France and the United Kingdom are major markets, although older ARBs with extensive generic competition can restrict azilsartan share.
Asia-Pacific is the fastest-growing major region. WHO reported more than 273 million people with hypertension in South-East Asia in 2026, while China is projected to reach approximately USD 180 million in azilsartan market value by 2034. Japan also has long-standing familiarity with azilsartan-based therapy.
Brazil, Mexico and other urban markets have large hypertension burdens and expanding generic access. Price sensitivity favors generics and fixed-dose combinations when reimbursed or competitively priced.
GCC countries have strong chronic-disease treatment infrastructure, while broader African adoption is limited by diagnosis gaps, medicine availability and healthcare access. Hypertension control remains a major public-health priority across the region.
Azilsartan is an established prescription ARB with current regulatory, generic and guideline support, but its use remains shaped by class-wide safety precautions.
| Regulatory / Clinical Element | Current Position | Market Effect |
|---|---|---|
| Current U.S. label | Azilsartan medoxomil tablets are marketed in 40 mg and 80 mg strengths and are indicated for adult hypertension. | Defines the core U.S. commercial market. |
| Recommended adult dose | 80 mg once daily for most adults; consider 40 mg in patients treated with high doses of diuretics. | Supports 80 mg as the principal maintenance strength. |
| First single-agent generic | Lupin received first generic approval for 40 mg and 80 mg in July 2022. | Introduced direct price competition. |
| First combination generic | Alkem received first generic approval for azilsartan medoxomil/chlorthalidone in January 2025. | Expands lower-cost fixed-dose combination access. |
| 2025 AHA/ACC guideline | Lists azilsartan 40–80 mg once daily among ARB options and favors two first-line agents for stage 2 hypertension when appropriate. | Supports combination-therapy positioning. |
| Boxed warning | Current labeling warns of fetal toxicity from renin-angiotensin system exposure. | Restricts use during pregnancy. |
The market has shifted from a single-originator environment toward a more competitive generic landscape, with national and regional manufacturers using price, distribution and combination products to gain share.
Takeda developed and launched Edarbi and remains associated with the originator molecule and manufacturing infrastructure. The core source model assigns the originator franchise the largest global share.
Lupin received first U.S. generic approvals for azilsartan medoxomil 40 mg and 80 mg tablets in July 2022, establishing a direct generic pathway for the single-agent product.
Alkem received first generic approval for azilsartan medoxomil/chlorthalidone 40/12.5 mg and 40/25 mg tablets in January 2025 and qualified for 180-day exclusivity subject to statutory conditions.
DailyMed shows a current azilsartan medoxomil NDA label updated in April 2026 with 40 mg and 80 mg products marketed from April 27, 2026.
Generic manufacturers compete through local registrations, payer contracting, API integration and lower pricing across Asia, Latin America and other markets.
27 April 2026: Wilshire Pharmaceuticals began marketing 40 mg and 80 mg azilsartan medoxomil tablets under NDA 200796, following a current DailyMed label update dated 20 April 2026.
17 May 2026: WHO's World Hypertension Day 2026 update reiterated that approximately 1.4 billion people live with hypertension globally and that only about one in four have adequate blood-pressure control.
21 January 2025: FDA granted first generic approval to Alkem Laboratories for azilsartan medoxomil/chlorthalidone tablets in 40/12.5 mg and 40/25 mg strengths.
14 August 2025: The 2025 AHA/ACC high-blood-pressure guideline was published, retaining ARBs as first-line antihypertensive agents and listing azilsartan at 40–80 mg once daily.
The global Azilsartan market is projected to grow from USD 605.2 million in 2026 to USD 850 million by 2034, at a 4.3% CAGR. Growth will be supported by the large uncontrolled hypertension population, combination therapy and improving generic access, while older low-cost ARBs and pricing pressure limit faster revenue expansion.
| Forecast Variable | Current Direction | Expected Effect Through 2034 |
|---|---|---|
| Hypertension burden | 1.4 billion adults globally had hypertension in 2024. | Sustains large long-term treatment demand. |
| Control gap | Only about 23% of affected adults had controlled blood pressure. | Creates room for treatment intensification. |
| Generic penetration | Single-agent and fixed-dose generic competition is expanding. | Improves access but compresses price. |
| Combination therapy | Guidelines support multi-drug treatment for stage 2 hypertension. | Raises combination-product opportunity. |
| Asia-Pacific | Large patient populations and improving medicine access support faster growth. | Creates strongest incremental volume growth. |
The study supports cardiovascular portfolio strategy, generic-market planning, pharmacy-channel analysis, combination-product positioning and competitive benchmarking.
Market sizing combines bottom-up product, supplier, procedure or prescription, and pricing analysis with top-down demand validation. Quantitative inputs include patient or procedure volumes, product mix, replacement or prescription cycles, end-user structure, regional access, pricing and adoption of newer technologies.
Primary research validates purchasing or prescribing criteria, clinical workflow, adoption barriers and competitive positioning. Secondary research prioritizes regulators, public-health agencies, professional bodies, peer-reviewed literature and official manufacturer information. Forecast assumptions are cross-checked against demographics, treatment access, regulatory activity, product launches and regional healthcare capacity.
Forecasts incorporate global hypertension prevalence, treated and controlled patient populations, 40 mg versus 80 mg product mix, generic penetration, combination therapy, pharmacy channels, regional price levels and competition from other ARBs. North America remains the largest value market, while Asia-Pacific receives the strongest volume-growth assumptions.
The market was valued at USD 580 million in 2025 and is estimated at USD 605.2 million in 2026. It is projected to reach USD 850 million by 2034, representing a 4.3% CAGR.
Azilsartan is an angiotensin II receptor blocker used to treat hypertension and lower the risk associated with persistently elevated blood pressure.
Current U.S. products are available as 40 mg and 80 mg tablets.
Current U.S. labeling recommends 80 mg once daily for most adults, with consideration of a 40 mg starting dose in patients receiving high-dose diuretics.
North America is the largest regional market, while Asia-Pacific is the fastest-growing major region.
Lupin's first single-agent generic approval and Alkem's first azilsartan/chlorthalidone generic approval have expanded competition and lowered barriers to access.
The report profiles Takeda, Lupin, Jiangsu Hengrui, Cipla, Dr. Reddy's, Zydus, Teva, Aurobindo, Viatris, Sun Pharma, Glenmark, Torrent, Wockhardt, Micro Labs, USV, Wilshire/Azurity and Alkem.
The public overview uses 2025 as the base year, 2026 as the estimated year and 2026–2034 as the forecast period.
Review the report scope, forecast timeframe, methodology, and cited evidence before deciding whether the full study fits your requirement.
Coverage, segmentation, geography, and market boundaries are stated within the report.
Readers can review the published sources and evidence referenced in this market overview.
Base, estimated, and forecast years are shown to place the market outlook in context.
Each overview displays its report identifier and latest update date.
A structured view of market size, forecast outlook, segmentation, regional dynamics, competitive activity, and the research framework behind this study.
Review the market estimate, growth outlook, forecast direction, and key factors influencing future demand.
Understand the report’s defined segments, demand drivers, applications, end users, and market opportunities.
Assess regional performance, selected country context, and factors shaping adoption across major markets.
Explore company profiles, market positioning, and selected developments relevant to the market landscape.
Review key demand drivers, challenges, emerging opportunities, technology shifts, and factors influencing market direction.
Understand the report scope, market boundaries, research approach, and evidence referenced in the published market overview.